US 12,251,379 B2
Methods of inhibiting formation of alpha synuclein aggregates
Bruce D. Hammock, Davis, CA (US); Sung Hee Hwang, Woodland, CA (US); Kenji Hashimoto, Chiba (JP); and Qian Ren, Chiba (JP)
Assigned to THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US); and CHIBA UNIVERSITY, Chiba (JP)
Appl. No. 16/967,115
Filed by THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US); and CHIBA UNIVERSITY, Chiba (JP)
PCT Filed Feb. 5, 2019, PCT No. PCT/US2019/016717
§ 371(c)(1), (2) Date Aug. 3, 2020,
PCT Pub. No. WO2019/156991, PCT Pub. Date Aug. 15, 2019.
Claims priority of provisional application 62/626,685, filed on Feb. 6, 2018.
Prior Publication US 2021/0161881 A1, Jun. 3, 2021
Int. Cl. A61K 31/453 (2006.01); A61K 31/198 (2006.01); A61K 31/415 (2006.01); A61K 31/4525 (2006.01); A61K 31/454 (2006.01); A61K 31/4545 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01); A61P 25/28 (2006.01); C12N 15/113 (2010.01)
CPC A61K 31/453 (2013.01) [A61K 31/198 (2013.01); A61K 31/415 (2013.01); A61K 31/4525 (2013.01); A61K 31/454 (2013.01); A61K 31/4545 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); A61P 25/28 (2018.01); C12N 15/1137 (2013.01); C12N 2310/14 (2013.01)] 9 Claims
OG exemplary drawing
 
1. A method of mitigating Parkinson's disease in a subject, said method comprising:
administering, to the subject an inhibitor of soluble epoxide hydrolase (sEHI) in an amount sufficient to mitigate Parkinson's disease, wherein the sEHI is a compound of Formula (II)

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof,
wherein X is C(O)
each R1 is H, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, or C1-6 haloalkoxy, wherein
at least 1 R1 is other than H;
R2 is C1-6 alkyl or C1-6 haloalkyl; and
subscript n is 1, 2, 3, 4, or 5.